Clinical Trial

IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML

Name: IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML — clinical trial record (NCT06418776)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The primary objective is to evaluate the efficacy and toxicity of high versus low intensity therapy options in patients with refractory forms and early relapses of acute myeloid leukemia (R/R AML) who are scheduled for allogeneic hematopoietic stem cell transplantation (alloHSCT).

Trial Details

NCT Number	NCT06418776
Lead Sponsor	National Research Center for Hematology, Russia Collaborators: St. Petersburg State Pavlov Medical University, Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Conditions	Refractory Acute Myeloid Leukemia, Early Relapses of Acute Myeloid Leukemia
Enrollment	198 participants
Start Date	2024-04-01
Primary Completion	2027-04 (estimated)
Study Completion	2029-05 (estimated)
Updated on ClinicalTrials.gov	2024-05-17